Announcements

2016 Spring/Summer Newsletter Released

The CRN 2016 Spring/Summer edition of the newsletter, The Cystinosis Advocate, is available now. Please go to the News/Newsletter link to view it.

KDIGO Cystinosis Conference Report Now Available

The meeting report from the Kidney Disease: Improving Global Outcomes (KDIGO) Cystinosis Controversies Conference is now published in the June issue of Kidney International and is also available at the KDIGO website as well as on the CRN website in the Article Library. Christy Greeley, CRN Executive Director, served as an patient advocacy representative and participated in the adolescent topic workgroup at the meeting held in December 2014 in Lisbon, Portugal. The report serves as an excellent update, enhancing our knowledge on the pathophysiology, diagnosis, and management of cystinosis.

Dr. Galina Nesterova Joins CRN's Medical Advisory Board

Dr. Galina Nesterova completes CRN NIH Clinical Fellowship, takes position in Vancouver, B.C.

Dr. Galina Nesterova has completed her 6 year CRN NIH Clinical Fellowship under the direction of Dr. Bill Gahl and has accepted a position at BC Children's Hospital of British Columbia, Vancouver, B.C. Patients can contact Dr. Nesterova via email at either This email address is being protected from spambots. You need JavaScript enabled to view it. or This email address is being protected from spambots. You need JavaScript enabled to view it.

The Cystinosis Research Network is indebted to Dr. Nesterova for dedicating a significant portion of her career to the treatment of hundreds of individuals with cystinosis. She has become an expert in the disorder and continues to be one of our community's greatest advocates.

We are pleased to announce that she will be joining CRN's Medical Advisory Board and will thus continue her outstanding service to the cystinosis community.

Raptor’s PROCYSBI® New Drug Submission Accepted by Health Canada with Priority Review

NOVATO, Calif., March 21, 2016 -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI® (cysteamine bitartrate) delayed-release capsules for the treatment of nephropathic cystinosis (NC), with Priority Review status. Priority Review provides for a shortened review process of 180 days compared to a standard 300 days. Raptor estimates, based on information provided by physicians, that there are approximately 100 individuals affected by nephropathic cystinosis in Canada. PROCYSBI, a cystine depleting agent, is approved in the U.S. for the treatment of NC in adults and children ages two years and older and in all patients with NC in Europe.

“I am pleased that PROCYSBI has been accepted for review in Canada and that the review process will be expedited,” said Krishna Polu, M.D., Chief Medical Officer of Raptor Pharmaceutical Corp. “There are currently no approved cystine depleting agents in Canada and the Priority Review status by Health Canada acknowledges the urgent unmet need Canadian patients with Cystinosis have for accessing PROCYSBI.”

CRN Announces 2016 Scholarship Application Deadline

It is that time of the year again. From now until the deadline date of Aug. 15, 2016, CRN will be accepting applications for our two, annual $1,000 Scholarships. The first is an Academic Scholarship for an individual with Cystinosis, and the second is the Sierra Woodward Sibling Scholarship for the sibling of an individual with cystinosis. Both scholarships are offered to qualified individuals who have been accepted at, or are attending an accredited college, university, or vocational school. Application information and needed forms can be accessed on CRN’s website at: www.cystinosis.org/scholarships. Completed materials should be mailed to:

CRN Scholarship Committee

C/O Terri Schleuder

40472 Franklin Mill St.

Novi, MI 48375

Materials need to be received by August 15, 2016 to be considered.

Advocates in Washington, D.C.

Over two hundred advocates (including some of our CRN families) were in Washington, D.C. as part of Rare Disease Week on Capitol Hill. You may have heard of a piece of legislation called the OPEN ACT (Orphan Product Extensions Now, Accelerating Cures & Treatments) that could double the number of treatments available to rare disease patients. This bipartisan bill could bring hundreds of safe, effective, and affordable medicines to rare disease patients within the next several years by incentivizing drug makers to repurpose therapies for the treatment of rare diseases.

We need your help to make this bill a law. Contact your legislators http://www.congressweb.com/KAKI/48 and ask them to co-sponsor the OPEN ACT.